Brammer Bio, a viral vector contract development and manufacturing organization (CDMO), has implemented a three-year, $200 million investment program at its Alachua, FL facilities, that will establish more than 30 suites for clinical and commercial viral vector supply for a broad pipeline of gene therapies and gene-modified cell therapies.
 
“Brammer’s vision is to enable innovators to bring these advanced medicines to patients. We are committed to continuing our investment in our world-class team and facilities for manufacturing gene therapies,” said Brammer Bio president and chief executive officer Mark Bamforth. “Brammer is uniquely positioned to support the dramatic growth of the gene and cell therapy sector through the application of our team’s deep technical and operational experience in developing and manufacturing gene therapies and gene-modified cell therapies.”
 
This expansion follows a doubling of its clinical capacity in Alachua in 2017, where the company employs more than 220 staff in a three-building campus totaling 80,000 sq.-ft. The site incorporates equipment and design concepts for process and analytical development for clinical trials and ultimately commercial scale manufacturing.
 
Brammer is conducting a further expansion of its first commercial facility in Cambridge, MA, increasing the number of commercial suites from 7 to 12, supporting up to 2,000-liter suspension and adherent processes. Construction will be completed in 1H19. Brammer acquired its Cambridge facility, as well as a distribution center in Somerville, MA, from Biogen in January 2017. These facilities are operated by a team of over 250 providing suspension processes to produce multiple vector products in support of late-stage clinical programs leading to commercial supply.
 
In Lexington, MA, Brammer is renovating a 50,000 sq.-ft. facility as its second commercial facility for adherent processes using the Pall iCELLis 500 platform. Construction will be completed 1H19.